Mon, Jan 26, 2015, 12:28 AM EST - U.S. Markets open in 9 hrs 2 mins


% | $
Quotes you view appear here for quick access.

Hemispherx Biopharma, Inc. Message Board

  • settoplunge settoplunge Jun 14, 2009 7:12 PM Flag

    If You're Slow, You Blow

    Novartis takes lead position in frenzied race for new flu vax
    June 12, 2009 — 7:15am ET | By John Carroll

    Novartis appears to be the first of the major vaccine makers to get through the critical first phase of development for a new vaccine to guard against the new flu.

    "Novartis has successfully completed the production of the first batch of influenza A (H1N1) vaccine, weeks ahead of expectations," the pharma giant announced in a statement. Clinical trials are now scheduled to begin next month with a license to begin large scale manufacturing expected in the autumn. And Novartis said that it appeared that the jab would be faster to make through the new cell-based approach to manufacturing rather than the traditional egg-based technology that has dominated the industry for decades.

    But Novartis isn't the only developer racing to the clinic with a new vaccine. At least 20 vaccine makers are scrambling to satisfy the growing clamor for vaccine supplies, especially after the World Health

    Organization has now declared what most vaccine experts already concluded: Swine flu has established itself in more than one continent and will easily slip through borders around the world. The virus, while mild, has already appeared in 74 countries.

    Sanofi-Aventis told Reuters, meanwhile, that it would be able to make the largest amount of swine flu vaccine in the shortest time frame, with the initial amount of bulk quantity available in about four months.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.2158-0.0092(-4.09%)Jan 23 4:01 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.